ABSTRACT OBJECTIVES This study investigates the influence of implantation depth and prosthesis oversizing on conduction abnormalities (CA) and permanent pacemaker implantation (PPI) after SAPIEN 3 (Edwards Lifesciences, Irvine, California) implantation.
P ost-procedural new or worsened conduction abnormalities (CA) and permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remain a serious concern.
The incidence of new or worsened CA, in particular complete left bundle branch block (LBBB) and PPI with balloon-expandable valves has been reported to be between 8% and 30% (1-5) and 5% and 12% (6) (7) (8) , respectively. Although PPI does not seem to affect survival (9, 10) , overall costs and hospital stay are increased (11) and symptomatic benefit may be limited (12) . New or worsened CA may negatively affect left ventricular function recovery and increase the risk for PPI during follow-up (13, 14) .
Recently, a balloon-expandable prosthesis (SAPIEN 3, Edwards Lifesciences, Irvine, California) (15) has been introduced featuring a higher metal frame with an outer skirt designed to avoid paravalvular leakage. The clinical experience with this device is limited, but first results are excellent (16) . However, regarding post-procedural PPI, preliminary studies report a relatively high rate, ranging from 13% to 25.5% (16) (17) (18) .
The development of new devices should weigh potential improvements, like minimizing paravalvular leakage and vascular complications, against an increase in PPI and CA. Minimizing these complications is mandatory for further improvement in TAVR outcome, especially in intermediate-risk patients. Therefore, determinants of PPI and CA need to be identified. Possible causes include technical issues, but also the appropriateness of sizing algorithms.
We aimed to examine potential determinants of new PPI and CA with the SAPIEN 3 valve using clinical, electrocardiographic, angiographic, and CTmorphological parameters.
METHODS
PATIENT POPULATIONS. We treated 244 consecutive patients with the SAPIEN 3 valve at our institution. TAVR was performed in a hybrid operation suite under general anesthesia or conscious sedation using the transfemoral approach. All patients provided written informed consent for the procedure.
To determine the incidence of new PPI after TAVR, 
Husser et al. Figure 1 and previous section). 
RESULTS
Clinical baseline, electrocardiographic, and procedural characteristics of the study population are displayed in Tables 2 and 3 . Mean age was 81 years with a logistic EuroSCORE of 16%. TAVR was performed using the 23-, 26-, and 29-mm SAPIEN 3 valve in 44%, 38%, and 18% of cases, respectively. Device success was achieved in 98%, with post-procedural paravalvular insufficiency $2 in 2% of cases.
Conscious sedation was used in 39% of cases. Median hospital stay was 5 days, and there was no in-hospital death.
Implantation depth (% of frame height below the aortic annulus) was evaluated in 207 patients (1 case was performed under echocardiographic guidance without contrast administration due to pre-operative severe renal failure). Mean implantation depth was 26 AE 7% (range 6% to 48%, Table 3 ).
MSCT data and degree of oversizing are displayed in Tables 4 and 5 for PPI is provided in Online Table 1 . Intraventricular conduction at baseline and discharge is displayed in Figure 4A . Patients undergoing PPI had a higher prevalence of atrial fibrillation (44% vs. 24%;
and bradycardia (<60 beats/min, 38% vs. 21%; p ¼ 0.034) ( Table 2 ) at baseline.
Depth of implantation and its association with PPI are displayed in Table 3 . Patients with PPI had a trend toward deeper implantation, especially at the nonseptal side, without statistical significance. Postdilation was not associated with PPI (32% vs. 35%;
In MSCT data, the degree of oversizing and adherence to sizing recommendations are displayed in Tables 4 and 5 . ) to obtain the degree of area oversizing (14.8%). Note that minimal and maximal diameters were not automatically obtained but were manually drawn to allow for an approximation of annulus eccentricity. For details, see the Methods section.
ACC ¼ non (a-)coronary cusp; LCC ¼ left coronary cusp; RCC ¼ right coronary cusp. frame height (long arrows) and the portion below the aortic annulus (short arrows) were measured at the septal (i.e., noncoronary cusp) and nonseptal (i.e., left coronary cusp) sides. Implantation depth was expressed as percentage of frame height below the aortic annulus.
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The independent predictors for new or worsened CA or PPI were implantation depth at the septal side However, there was no difference in incidence of new or worsened CA or PPI across the tertiles of consecutive cases (p for the trend ¼ 0.962) (Online Figure 1) .
DISCUSSION
In the present study, we report the rate of PPI and new or worsened CA with the SAPIEN 3 device. Additionally, PPI after TAVR has been identified as an important cause of prolonged hospital stay, thereby increasing procedural costs (11) .
There are still limited available data on the incidence of PPI after TAVR with the SAPIEN 3 valve, although emerging figures indicate a rate of PPI between 13% and 25.5% (16) (17) (18) . In a preliminary series analyzing the SAPIEN 3 prosthesis, our group found a PPI rate of 12.5% (24) . With increasing experience, this rate was not reduced and was 16% in this extended patient cohort, which is in line with the mentioned reports from the published data.
There are other reasons for an elevated PPI rate apart from device-or technical-related causes.
One reason may be a substantial percentage of pre-existent RBBB. As reported in previous studies (25) and in a recent meta-analysis (8), pre-existing RBBB is a strong predictor for PPI after TAVR. This was also observed in our study, where baseline ECG parameters were most important for the prediction of PPI.
The incidence of new or worsened CA after TAVR with balloon-expandable valves ranges between 8% and 30% (1) (2) (3) (4) (5) . Although no effect on mortality could be demonstrated (2) , new or worsened CA are LVOT ¼ left ventricular outflow tract; MSCT ¼ multislice computed tomography; other abbreviations as in Table 3 .
Predictors of PPI in S3 Values are n (%).
MSCT ¼ multislice computed tomography; other abbreviations as in Table 3 .
PPI. This should be considered in future sizing recommendations.
A somewhat counterintuitive finding in this study is the weak relationship between PPI and both over- Intraventricular conduction at baseline and before discharge in the population for PPI analysis (A) and for new or worsened CA or PPI (B).
Abbreviations as in Figure 1 .
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